GIMV NV (ENXTBR:GIMB) reached an agreement to acquire 20.87% stake in Bioconnection B.V. from Pharming Group N.V. (ENXTAM:PHARM) for 6.9 million on April 22, 2022. Pharming will receive one-off 6.9 million net cash proceeds in Q2 2022. Pharming will continue to support BioConnection to accelerate its next stage of growth to further invest in its organization and infrastructure to increase the production capacity.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
0.881 EUR | -2.60% | +1.50% | -14.55% |
Apr. 22 | Pharming Group to Buy Back EUR123 Million of Bonds due 2025 | MT |
Apr. 18 | Pharming Group to Issue EUR100 Million Convertible Bonds, Repurchase EUR125 Million Bonds | MT |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-14.55% | 651M | |
+24.17% | 562B | |
-6.33% | 358B | |
+19.90% | 322B | |
+7.95% | 297B | |
+13.45% | 219B | |
+6.04% | 199B | |
-10.51% | 196B | |
-12.26% | 149B | |
-6.47% | 146B |
- Stock Market
- Equities
- PHARM Stock
- News Pharming Group N.V.
- GIMV NV reached an agreement to acquire 20.87% stake in Bioconnection B.V. from Pharming Group N.V. for €6.9 million.